Why the study?
What are the pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in healthy elderly subjects?
What are the pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in healthy elderly subjects?
Single doses of rivaroxaban up to 40 mg show predictable pharmacokinetics and are well tolerated in healthy elderly subjects.
Answers are grounded in this paper and cite their sources.
Supports rivaroxaban dosing exploration up to 40 mg in elderly; leaves open confirmation in patients with comorbidities.
Each single dose of rivaroxaban was well tolerated, with predictable pharmacokinetics and pharmacodynamics at doses up to 40 mg, and provided effective anticoagulation in healthy elderly subjects. Adverse events were somewhat elevated in the 50 mg group, but given the small sample size, no specific conclusions can be drawn about this dosing level.
No takes yet. Share an insight, caveat, or question.
Kubitza et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: